166 related articles for article (PubMed ID: 8017004)
1. [The immunomodulating action of bestatin in the combined therapy of bladder cancer patients].
Neprina GS; Panteleeva ES; Vatin OE; Kariakin OB
Urol Nefrol (Mosk); 1994; (2):34-8. PubMed ID: 8017004
[TBL] [Abstract][Full Text] [Related]
2. Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients.
Blomgren H; Edsmyr F; von Stedingk LV; Wasserman J
Biomed Pharmacother; 1986; 40(2):50-4. PubMed ID: 3756312
[TBL] [Abstract][Full Text] [Related]
3. Immunological and haematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial.
Blomgren H; Edsmyr F; Esposti PL; Näslund I
Biomed Pharmacother; 1984; 38(3):143-9. PubMed ID: 6383491
[TBL] [Abstract][Full Text] [Related]
4. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
5. [The immune homeostasis of patients with prostatic cancer on hormonal chemotherapy, radiation treatment and immunological action].
Panteleeva ES; Sviridova TV; Neprina GS; Sirotkina NP
Urol Nefrol (Mosk); 1996; (1):28-31. PubMed ID: 8659039
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant bestatin (Ubenimex) treatment following full-dose local irradiation for bladder carcinoma.
Blomgren H; Esposti PL; Näslund I; Johansen L; Lemming O
Acta Oncol; 1990; 29(6):809-12. PubMed ID: 2223154
[TBL] [Abstract][Full Text] [Related]
7. Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator. A phase I study.
Blomgren H; Strender LE; Edsmyr F
Biomedicine; 1980 Dec; 32(4):178-85. PubMed ID: 7470579
[TBL] [Abstract][Full Text] [Related]
8. Bestatin therapy of patients with atopic dermatitis.
Thestrup-Pedersen K; Cramers M; Kongsholm H; Zachariae H
Acta Derm Venereol; 1983; 63(6):549-52. PubMed ID: 6198850
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulating properties of bestatin in cancer patients. A phase II trial.
Mathé G; Umezawa H; Misset JL; Brienza S; Canon C; Musset M; Reizenstein P
Biomed Pharmacother; 1986; 40(10):379-82. PubMed ID: 3495299
[TBL] [Abstract][Full Text] [Related]
10. [The intravesical administration of BCG vaccine in treating recurrent superficial bladder cancer].
Panteleeva ES; Neprina GS; Vatin OE; Kariakin OB; Safiullin KN
Urol Nefrol (Mosk); 1997; (2):29-32. PubMed ID: 9206879
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory and therapeutic properties of bestatin in mice.
Talmadge JE; Lenz BF; Pennington R; Long C; Phillips H; Schneider M; Tribble H
Cancer Res; 1986 Sep; 46(9):4505-10. PubMed ID: 2942238
[TBL] [Abstract][Full Text] [Related]
12. [A new antitumor drug with immunomodulating activity, ubenimex (bestatin)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2385-91. PubMed ID: 3496857
[TBL] [Abstract][Full Text] [Related]
13. [Effect of bestatin on immuno-suppressive acidic protein in patients with stomach cancer].
Ishii T; Takeshita K; Sunagawa M; Habu H; Hoshi K
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1585-90. PubMed ID: 6476836
[TBL] [Abstract][Full Text] [Related]
14. [Clinical studies of bestatin on genitourinary cancer].
Ichikawa T; Hirokawa I; Ishihara Y
Jpn J Antibiot; 1985 Jan; 38(1):166-78. PubMed ID: 3989976
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial.
Blomgren H; Näslund I; Esposti PL; Johansen L; Aaskoven O
Cancer Immunol Immunother; 1987; 25(1):41-6. PubMed ID: 3594491
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of bestatin (NK-421) supplementing radiotherapy in the treatment of lung cancer].
Hamada F; Imajo Y; Inomata Y; Ichiyanagi A; Ashida C; Gose K; Imanaka K; Takada Y; Kimura S; Ogawa Y
Nihon Gan Chiryo Gakkai Shi; 1983 Aug; 18(5):1175-80. PubMed ID: 6663170
[No Abstract] [Full Text] [Related]
17. [Immunotherapy with bestatin for acute non-lymphocytic leukemia (ANLL) in adults].
Kurita S; Ota K; Yamada K; Massaoka T; Uzuka Y; Ogawa N
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2742-50. PubMed ID: 6508324
[TBL] [Abstract][Full Text] [Related]
18. [Experimental and clinical studies of bestatin as an immunomodulator].
Miwa H; Oka T; Tsurumi T; Sakae Y; Orita K
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1019-24. PubMed ID: 7184437
[TBL] [Abstract][Full Text] [Related]
19. [The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].
Shekarsarai H; Zlotta AR; Drowart A; Van Vooren JP; De Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
Acta Urol Belg; 1997 Mar; 65(1):1-4. PubMed ID: 9245197
[TBL] [Abstract][Full Text] [Related]
20. [Phase I study of Bestatin: (I) A clinical study on determination of an optimal dose of Bestatin].
Saito K; Miyasato H; Tajima K; Ikeda S
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):211-7. PubMed ID: 6881973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
